Morgan Stanley initiated coverage on enGene Holdings with a new price target

3/8/24 7:33:02 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Morgan Stanley initiated coverage of enGene Holdings with a rating of Overweight and set a new price target of $40.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ENGN

Date	Price Target	Rating	Analyst
2/18/2025	$26.00	Overweight	Piper Sandler
2/14/2025	$34.00 → $7.00	Buy → Neutral	UBS
12/23/2024	$25.00	Buy	H.C. Wainwright
11/27/2024	$23.00	Outperform	Raymond James
11/18/2024	$18.00	Mkt Outperform	JMP Securities
8/28/2024	$30.00	Outperform	Oppenheimer
4/22/2024	$30.00	Overweight	Wells Fargo
4/15/2024	$34.00	Buy	Guggenheim